The focus of the industry on living human beings and highly controlled standards make it a unique challenge for business leaders. These attributes make the industry https://genotec-frankfurt.de/biotechnological-synthesis-of-remedies/ a natural incubator for innovations, which has led to significant breakthroughs that have increased agricultural yields, created biofuels and led to life-saving pharmaceutical products.
Start-up biotech companies have many options when it comes to revenue generation strategies, with the majority choosing either a technology partnership or an approach to asset creation and out-licensing. Technology partnering can bring faster revenue and lower financial risk, whereas strategies for asset creation and outlicensing can yield greater returns. A growing number of biotechs that are in research phase operate in a hybrid approach that combines both strategies.
Those who opt for the approach of developing based on products can be successful commercially when they are able to get their pipeline up to the right stage and attract a large pharmaceutical partner or investor with deep pockets. This is a costly proposition however, and balancing opportunistic approaches to leveraging outside resources while making the right scientific decision-making about projects that are homegrown is key.
Alternatively, the “platform” model can provide an alternative route to earning revenue. It’s a cheaper method than the development-oriented model however it carries substantial risks. In this model, a biotech owns and develops its platform technology prior to collaboration with big pharma firms to develop a portfolio of drug discovery projects that are targeted at specific disease areas (i.e., disease x in biology y). This is the strategy Advinus Therapeutics and a few others have adopted.